Novartis has reported new Phase III data showing that its investigational monoclonal antibody ianalumab, in combination with eltrombopag, significantly extended disease control in adults with primary immune thrombocytopenia (ITP) who had previously failed corticosteroid therapy. The VAYHIT2 trial achieved both its primary endpoint of time to treatment failure and a key secondary endpoint of sustained platelet response at six months. The treatment regimen involved only four once-monthly intravenous doses of ianalumab. Novartis plans regulatory submissions in 2027, pending results from the ongoing VAYHIT1 first-line trial.

Why Novartis’ ianalumab could mark the end of indefinite maintenance therapy in ITP

The VAYHIT2 results challenge the chronic-care mindset that dominates ITP treatment today. Current second-line therapies, particularly thrombopoietin receptor agonists such as eltrombopag and romiplostim, often require long-term or lifelong use. These agents stimulate platelet production but do not address the underlying autoimmune process. Patients frequently rotate through therapies due to lack of durability, convenience, or tolerability.

By contrast, ianalumab showed that a four-dose course delivered a median time to treatment failure of 13 months, nearly three times longer than the placebo plus eltrombopag group. This durability of response, combined with an improved fatigue profile, points to a potential shift from ongoing disease suppression to finite, remission-inducing therapy.

What makes ianalumab’s dual mechanism different from legacy options like rituximab

Ianalumab is not simply another B-cell depleting agent. While it does induce B-cell elimination through antibody-dependent cytotoxicity, it also blocks the BAFF-R survival pathway that helps sustain autoreactive B-cell populations. This two-pronged approach sets it apart from older therapies such as rituximab, which has long been used off-label in ITP but delivers inconsistent results and lacks durability.

The combination of ianalumab and eltrombopag in VAYHIT2 led to a sustained platelet response at six months in 62 percent of patients, compared to just 39 percent in the placebo arm. Importantly, this immune modulation also translated into a clinically meaningful 7.7-point improvement in fatigue scores, a symptom often underreported in ITP trials but highly relevant to patients.

VAYHIT2 trial design provides clarity on dosing and statistical strength

The Phase III trial enrolled adult patients with primary ITP who had platelet counts below 30 G/L despite prior corticosteroid treatment. All participants continued eltrombopag as a background therapy and were randomized to receive either ianalumab at 9 mg/kg, 3 mg/kg, or placebo—each as four once-monthly infusions.

Only the 9 mg/kg dose demonstrated statistically significant improvement in both the primary endpoint (time to treatment failure) and the key secondary endpoint (stable platelet response at six months). The 3 mg/kg dose showed statistical significance for the primary endpoint but only numerical improvement in secondary outcomes.

These results suggest a clear dose–response relationship, which may streamline regulatory review and inform future prescribing. The trial’s robust blinding and randomization structure further adds to the credibility of its findings.

How Novartis’ data signal a broader shift toward fixed-duration autoimmune therapies

The concept of fixed-duration treatment is gaining ground across autoimmune conditions, particularly as biologics mature and mechanistic targets become better understood. With ianalumab, Novartis appears to be positioning itself at the front of this trend, emphasizing finite induction over indefinite maintenance.

The ability to offer ITP patients a limited-course therapy with durable benefit could reduce the cumulative toxicity, emotional burden, and cost associated with current regimens. Clinicians tracking autoimmune hematology note that such an approach mirrors the evolution seen in other chronic immune-mediated diseases, such as rheumatoid arthritis and systemic lupus erythematosus, where induction–maintenance models are increasingly replacing one-size-fits-all strategies.

Ianalumab safety profile is favorable but neutropenia remains a watch item

Safety data from VAYHIT2 were consistent with previous ianalumab studies. The most commonly reported adverse events were headache and infusion-related reactions, both occurring at similar rates across treatment and placebo arms. However, neutropenia was observed more frequently in the ianalumab arms—16 percent at 9 mg/kg and 12 percent at 3 mg/kg—compared to 2 percent in the placebo group.

Although most cases resolved without treatment interruption, the elevation in neutropenia rates will likely attract scrutiny during regulatory review. There is also limited long-term data on immune system reconstitution following B-cell depletion, an area where post-marketing surveillance may be needed to assess infection risk and autoimmune relapse.

What makes this a pivotal moment in the autoimmune hematology pipeline

Ianalumab is being developed across multiple B-cell–driven indications, including Sjögren’s disease, systemic lupus erythematosus, lupus nephritis, warm autoimmune hemolytic anemia, and diffuse cutaneous systemic sclerosis. The compound has already delivered two positive Phase III trials in Sjögren’s disease, and the VAYHIT2 results mark its third late-stage win.

The broader pipeline strategy suggests that Novartis envisions ianalumab as a modular biologic platform applicable across multiple diseases with shared pathophysiology. Industry observers have noted that its BAFF-R blockade differentiates it from other B-cell agents, including CD20- and CD19-targeted therapies.

With B-cell–targeted immunotherapies dominating the autoimmune development landscape, Novartis’ ability to demonstrate durable, off-treatment benefit across indications could place ianalumab in a first-mover position in the emerging field of remission-oriented biologics.

Key questions still surround ianalumab’s regulatory and clinical positioning

Despite the strength of the VAYHIT2 results, the path to approval is not without complications. Novartis has stated that it will not submit regulatory filings until 2027, when results from the ongoing first-line VAYHIT1 trial are available. This delay opens a window for competitive agents or biosimilars to gain traction.

Another open question is how payers and health systems will value ianalumab. Without direct head-to-head trials against rituximab or other immunomodulators, it may be difficult to define its cost–benefit ratio, especially given its intravenous administration. Additionally, while the four-dose protocol is attractive from a patient compliance standpoint, IV infusions can still be a barrier in outpatient hematology settings without infusion infrastructure.

Clinicians will also be eager to understand whether ianalumab can be used as monotherapy or must remain paired with eltrombopag. Since all VAYHIT2 patients received background eltrombopag, the standalone efficacy of ianalumab remains an unanswered question.

Conclusion: Novartis raises the bar for what ITP therapies should deliver

The VAYHIT2 results put Novartis in a strong position to shift expectations in ITP care. With just four doses of ianalumab, patients saw nearly threefold improvements in time to relapse and significant gains in both platelet stability and fatigue reduction. These outcomes suggest a potential future where remission—not just control—is achievable in a disease long dominated by chronic treatment cycles.

If VAYHIT1 replicates these findings in the first-line setting and long-term safety data remain favorable, ianalumab could become the standard against which future ITP biologics are measured. In the broader autoimmune pipeline, it is shaping up to be a test case for the success of finite-duration biologics that prioritize quality of life and long-term disease quiescence.

  autoimmune disease, B cell therapy, eltrombopag, hematology, ianalumab, immune thrombocytopenia, ITP, monoclonal antibody, Novartis, Phase III trials, VAYHIT2